Bahram Valamehr - Sep 13, 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Development Officer
Signature
/s/ Cindy Tahl, Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Sep 13, 2021
Transactions value $
-$1,589,007
Form type
4
Date filed
9/14/2021, 04:01 PM
Previous filing
Jun 16, 2021
Next filing
Nov 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $68.3K +25K +26.11% $2.73 121K Sep 13, 2021 Direct F1
transaction FATE Common Stock Sale -$1.04M -15.8K -13.09% $65.94* 105K Sep 13, 2021 Direct F1, F2
transaction FATE Common Stock Sale -$561K -8.39K -8% $66.84* 96.5K Sep 13, 2021 Direct F1, F3
transaction FATE Common Stock Sale -$54K -800 -0.83% $67.46* 95.7K Sep 13, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -25K -22.49% $0.00 86.2K Sep 13, 2021 Common Stock 25K $2.73 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 9, 2020.
F2 Represents the weighted average sale price of the shares sold from $65.40 to $66.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4.
F3 Represents the weighted average sale price of the shares sold from $66.40 to $67.38 per share.
F4 Represents the weighted average sale price of the shares sold from $67.40 to $67.54 per share.
F5 This option is fully vested.